Abstract
The present study was carried out in order to determine whether insulin-induced hypoglycemia exerts its stimulatory effect on plasma concentrations of arginine vasopressin (AVP) by interacting with a serotonergic, a GABA-ergic or an opioid pathway. For this purpose, the effect of the serotonergic antagonist metergoline (10 mg/day for 4 days po), the GABA-ergic agonist sodium valproate (600 mg in three divided doses po) and the opioid-receptor blocker naloxone (10 mg in a iv bolus) on the AVP response during an insulin (0.15 lU/kg bw) tolerance test (ITT) was evaluated in three groups of 6 normal men each. In all men, control ITTs were performed without drug treatments. Basal and ITT-stimulated AVP secretion was not modified by drug administration, suggesting that serotonergic, GABAergic and naloxone-sensitive opioid receptors are not involved in the regulation of AVP secretion in response to insulin-induced hypoglycemia.
Similar content being viewed by others
References
Baylis P.H., Zerbe R.L., Robertson G.L. Arginine vasopressin response to insulin-induced hypoglycemia in man. J. Clin. Endocrinol. Metab. 53: 935, 1981.
Tappaz M., Bronwnstein M.J., Kopin I. Glutamate decarboxylase (GAD) and x-aminobutyric acid (GABA) in discrete nuclei of hypothalamus and substantia nigra. Brain Res. 125: 109, 1977.
Palacios J.M., Wamsley J.K., Kuhar M.J. High affinity GABA receptors-autoradiographic localization. Brain Res. 222: 285, 1981.
Bicknell R.J. Endogenous opioid peptides and hypothalamic neuroendocrine neurones. J. Endocrinol. 107: 437, 1985.
Kamoi K., Robertson G.L. Opiates and vasopressin secretion. In: Schrier R.W. (ed.), Vasopressin. Raven Press, New York, 1985, p. 259.
van den Pol A.N. Dual ultrastructural localization of two neurotransmitterrelated antigens: colloid gold labeled neurophysin immunoreactive supraoptic neurons receive peroxidase labeled glutamate decarboxylase or gold labeled GABA immunoreactive synapses. J. Neurosci. 5: 2940, 1985.
van Wimersma Greidanus T.B., ten Haaf J.A., Mens W.B.J. The regulation of the function of the posterior pituitary with special reference to the role of opioid peptides. Front. Horm. Res. 14: 197, 1985.
De Souza E.B. Serotonin and dopamine receptors in the rat pituitary gland; autoradiographic identification, characterization, and localization. Endocrinology 119: 1534, 1986.
Theodosis D.T., Paut L., Tappaz M.L. Immunocytochemical analysis of the gabaergic innervation of oxytocin and vasopressin-secreting neurons in the rat supraoptic nucleus. Neuroscience 19: 207, 1986.
Mason W.T., Poulain D., Cobbett P. γ-aminobutyric acid as an inhibitory neurotransmitter in the rat supraoptic necleus: intracellular recordings in the hypothalamic slice. Neurosci. Lett. 73: 259, 1987.
Gibbs D.M., Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res. 280: 176, 1983.
Steardo L., Iovino M., Hunnicutt E. Evidence for a 5-HT involvement in vasopressin release from neurohypophysis of rats. 15th Annual Meeting of the Society of Neuroscience, 1985, p. 44.
Steardo L., Iovino M. Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral renin- angiotensin system. Brain Res. 382: 145, 1986.
Sladek C.D., Armstrong W.E. /-aminobutyric acid antagonists stimulate vasopressin release from organ-cultured hypothalamo-neurohypophyseal expiants. Endocrinology 120: 1576, 1987.
Van der Laan J.W., de Boer T., Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J. Neurochem. 32: 1769, 1979.
Beretta C., Ferrini R., Glässer A.H. 1, 6-dimethyl-8-carbobenzyl-oxy-aminomethyl-10-ergo- line, a potent and long-acting 5-hydroxy-tryptamine antagonist. Nature 207: 421, 1965.
Fuxe K., Agnati L., Everitt B. Effects of methergoline on central monoamine neurons. Evidence for a selective blockade of central 5-HT receptors. Neurosci. Lett. 1: 283, 1975.
Blumberg H., Dayton H.B. Naloxone and related compounds. In: Kosterliz H.W., Collier H.O.J., Villareal J.E. (Eds.), Agonist and antagonist actions of narcotic analgesic drugs. University Park Press, Baltimora, 1973, p. 110.
Chiodera P., Louis F., Legros J.J. Simultaneous radioimmunoassay for plasma argininevasopressin and oxytocin using DEAE sephadex A 25 extraction. J. Endocrinol. Invest. 7: 287, 1984.
Cavagnini F., Raggi U., Micossi P., Di Landro A., Invitti C. Effect of antiserotoninergic drug, metergoline, on the ACTH and Cortisol response to insulin hypoglycemia and lysine-vasopressin in man. J. Clin. Endocrinol. Metab. 43: 306, 1976.
Serri O., Rasio E., Somma M. Effects of naloxone on insulin-induced release of pituitary hormones. J. Clin. Endocrinol. Metab. 53: 206, 1981.
Petraglia F., Bakalakis S., Facchinetti F., Volpe A., Muller E.E., Genazzani A.R. Effects of sodium valproate and diazepam on beta-en- dorphin, beta-lipotropin and Cortisol secretion induced by hypoglycemic stress in humans. Neuroendocrinology 44: 320, 1986.
Kao C.P., N-Siang Jiang, Carpenter P.C. Human corticotropin (ACTH) radioimmunoassay with synthetic 1–24 ACTH. Clin. Chem. 25: 1267, 1979.
Schalch D.S., Parker M.L. A sensitive double antibody immunoassay for human growth hormone in plasma. Nature 203: 1141, 1964.
Baylis P.H. Posterior pituitary function in health and disease. In: Scanion M.F. (ed.), Neuroendocrinology. Saunders, Philadelphia, 1983, p. 747.
Coiro V., Butturini U., Gnudi A., Delsignore R., Volpi R., Chiodera P. Nicotinic-cholinergic involvement in arginine-vasopressin response to insulin-induced hypoglycemia in normal men. Metabolism 35: 577, 1986.
Adler G.K., Majzoub J.A. Influence of infused hypertonic saline on the response to insulin-induced hypoglycemia in man. J. Clin. Endocrinol. Metab. 65: 116, 1987.
Chiodera P., Coiro V. Lack of effect of bromocriptine and domperidone on arginine-vasopressin response to insulin-induced hypoglycemia in normal men. Psychoneuroendocrinology 12: 225, 1987.
Brennan T.J., Haywood J.R. GABAergic inhibition of hypertonic saline-induced vasopressin-dependent hypertension. J. Pharmacol. Exper. Therap. 233: 663, 1985.
lovino M., Steardo L. Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur. J. Pharmacol. 113: 99, 1985.
Lightman S.L., Langdon N., Forsling M.L. Effects of the opiate antagonist naloxone and the enkephalin analog DAMME on the vasopressin response to a hypertonic stimulus in man. J. Clin. Endocrinol. Metab. 51: 1447, 1980.
Lightman S.L., Forsling M.L. Evidence for endogenous opioid control of vasopressin release in man. J. Clin. Endocrinol. Metab. 50: 251, 1980.
Unger T., Bles F., Ganten D., Lang R.E., Retting R., Schwab N.A. GABAergic stimulation inhibits central actions of angiotensin II: pressor responses, drinking and release of vasopressin. Eur. J. Pharmacol. 90: 1, 1983.
Goodman Gilman A., Goodman L.S., Gilman A. The pharmacological basis of therapeutics. Mac Millan, New York, 1980, p. 946.
Goodman Gilman A., Goodman L.S., Gilman A. The pharmacological basis of therapeutics. Mac Millan, New York, 1980, p. 462.
Tepperman F.S., Hirst M., Smith P. Brain and serum levels of naloxone following peripheral administration. Life Sci. 33: 1091, 1983.
van Houten M., Posner B.I., Kopriwa B.M., Brawer J.R. Insulin-binding sites in the rat brain: in vivo localization to the circumventricular organs by quantitative radiography. Endocrinology 105: 666, 1979.
van Houten M., Posner B.J., Kopriwa B.M., Brawer J.R. Insulin binding sites localized nerve terminals in rat median eminence and arcuate nucleus. Science 207: 1081, 1980.
van Houten M., Nance D.M., Gauthier S., Posner B.I. Origin of insulin-receptive nerve terminals in rat median eminence. Endocrinology 113: 1393, 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chiodera, P., Gnudi, A., Volpi, R. et al. Metergoline, naloxone, and sodium valproate did not modify arginine vasopressin response to insulin-induced hypoglycemia in man. J Endocrinol Invest 11, 365–369 (1988). https://doi.org/10.1007/BF03349056
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349056